Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
Am J Otolaryngol
; 41(5): 102618, 2020.
Article
in English
| MEDLINE | ID: covidwho-612482
ABSTRACT
SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro virucidal action of povidone iodine in SARS CoV and MERS. The oropharynx and nasopharynx are target sites of SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles, PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries. AIMS:
MATERIALS ANDMETHODS:
0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution. Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for 30â¯s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior. Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4% xylocaine/adrenaline solution, tolerability and any allergic reaction noted.RESULTS:
The patient and health care workers tolerated the 0.5%. No allergy was noted.CONCLUSION:
We propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of spread of the disease in addition to the recommended PPE.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Otolaryngology
/
Pneumonia, Viral
/
Povidone-Iodine
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
/
Anti-Infective Agents, Local
Type of study:
Observational study
/
Prognostic study
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
/
Young adult
Language:
English
Journal:
Am J Otolaryngol
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS